Single use of MR-proANP or, for slightly improved utility, combined use of both biomarkers for ROP prediction on day seven of life would have allowed us to reduce the proportion of infants having ophthalmological examinations by about 60%, with a sensitivity of 100% for detection of ROP ≥ stage II. The gene discussed is NPPA; the disease is retinopathy of prematurity.